Medius Holdings Co., Ltd. · TSE:3154
Medius — FY2025 Earnings Presentation
48 slides from Medius's earnings presentation, Aug 8, 2025
Slide 1: Earnings Presentation Materials, Fiscal Year Ended June 30, 2025
Fiscal Year Ended June 30, 2025 Earnings Presentation Materials August 8, 2025 Medius Holdings Co., Ltd. Securities Code: 3154 Copyright©2025 Medius Holdings Co., Ltd. All Rights Reserved 1
Slide 2: Today's Key Points
Today’s Key Points Medical fee revision that came into effect in June 2024 has raised medical fees paid to doctors and hospitals but lowered drug prices and material prices. Meanwhile, the outlook surrounding our group remains uncertain, as costs have continued to rise due to high energy prices an
Slide 3: Financial Results for the FYE 6/2025
Financial Results for the FYE 6/2025 (Millions of yen, %) FYE June 2024 FYE June 2025 YoY (Results) (Results) Increase/ Amount Amount % of net sales Percentage decrease Net sales 259,789 288,689 100.0 28,900 111.1 Medical Device Sales Business 253,996 282,688 97.9 28,691 111.3 Welfare Device Busines
Slide 4: Group Companies
Group Companies As of June 30, 2025 Copyright©2025 Medius Holdings Co., Ltd. All Rights Reserved 4
Slide 5: Sales Locations
Sales Locations As of June 30, 2025 Copyright©2025 Medius Holdings Co., Ltd. All Rights Reserved 5
Slide 6: Medical Device Sales Customer Segments
Medical Device Sales Customer Segments Prefectural and municipal medical institutions 16.8% Japanese Red Cross hospitals 6.3% National Hospital Organization 3.7% Others Federations of Agricultural Prefectural and Cooperatives for Health and Welfare 2.6% municipal medical (Kouseiren) Clinics institut
Slide 7: Changes in Sales
Changes in Sales (Millions of yen) (%) 400,000 40 350,000 Net sales growing steadily 332,650 347,000 35 30 300,918 300,000 278,299 305,000 25 259,574 288,689 250,000 246,787 20 259,789 17.6% 210,388 17.3% 239,054 15 200,000 197,691 226,606 8.1％ 7.2％ 10 6.4% 10.5% 150,000 4.3% 5 5.2% After applicatio
Slide 8: Market Conditions for Medical Devices
Market Conditions for Medical Devices （％） (Billions of yen) 60,000 6.0 Market size Growth rate 53,985 Projected market size 48,419 50,000 5.0 43,427 38,950 40,000 36,270 37,340 38,190 4.0 34,570 35,240 32,830 33,550 30,000 3.0 2.2 2.0 3.0 20,000 2.9 3.0 2.0 2.2 1.9 2.3 2.0 5years 5years 5years 10,00
Slide 9: Medium-Term Business Plan: FYE 6/2026–FYE 6/2028
Medium-Term Business Plan: FYE 6/2026－FYE 6/2028 Reinforce existing businesses Ordinary profit Up 10% + Aim to expand scale through M & A annually Use ordinary profit as a key indicator to improve profitability and strengthen existing businesses. On the other hand, continue business expansion throug
Slide 10: Medium-Term Business Plan: Strategies to Enhance Corporate Value
Medium-Term Business Plan: Strategies to Enhance Corporate Value Contributing to Regional Medical Care Restructuring of Existing Businesses Policies & Measures Selective, Focused Business Investment Improve operational Strengthen human capital Cultivate a solid Improve capital efficiency Returns to
Slide 11: M&A & Alliance Strategy: Background
M&A & Alliance Strategy: Background ▼ Japan’s medical device market The market is projected to continue growing until 2040 as Japan’s society ages. There is plenty of scope for growing the top line. However, growth in Japan’s medical device market has slowed compared with previous years in an en
Slide 12: M&A & Alliance Strategy: What manufacturers want
M&A & Alliance Strategy: Background ▼What manufacturers want Manufacturers are focused on reducing costs (operating costs and logistics costs); they therefore want sales agents to undertake that role. They also want widespread operations, regional market shares, financial stability, capacity to
Slide 13: M&A Strategy: Medius Holdings M&A in Recent Years
M&A Strategy: Medius Holdings M&A in Recent Years (Subject to Consolidation) Year Month Target company Status at time of M&A Current status Became part of current ALVAUS, Inc. following restructuring 2020 Mar. Active Medical Co., Ltd. Consolidated subsidiary within the Group. Operations in the Hokka
Slide 14: Total Solutions Strategy
Total Solutions Strategy Medical Medical institutions are facing increasingly serious management challenges, including the need to respond to workstyle institutions reforms for doctors, declining revenues due to healthcare cost containment policies, and rising expenses such as utilities and labor co
Slide 15: Total Solutions Strategy: Solutions Lineup
Total Solutions Strategy: Solutions Lineup Medical institutions SPD SPD stands for Supply, Processing, and Distribution. It is a strategy originating in the US Increased for streamlining the management of distribution within hospitals. Total solutions + Manufa cturers efficiency Medius Group Our sol
Slide 16: Streamlining of Operations: For Manufacturers
Streamlining of Operations: For Manufacturers Medical institutions Manufacturers and medical device trading companies need to take action to address higher logistics Increased costs and reduced working hours. efficiency The Medius Group alleviates the associated burdens on manufacturers by picking u
Slide 17: Streamlining of Operations: Within the Medius Group
Streamlining of Operations: Within the Medius Group Medical institutions Consolidate Increased specialist efficiency domains Manufa Medius cturers Group Reorganize within the Targets for Establish Group Optimize streamlining shared procurement corporate & logistics operations Streamline the whole Gr
Slide 18: Topics: Established three new operating companies
Topics: Established three new operating companies Logistics Product Procurement Contract Sales Support Mediris Logistics Co., Ltd. MIUL Healthcare Co., Ltd. REPS Corp. July 2025 July 2025 July 2025 Spun off as a specialized company Product development division spun off. Contract business of KURIBARA
Slide 19: Topics: Advancing to the Next Stage
Topics: Advancing to the Next Stage Toward Unified Medical Information Infrastructure Nationwide Contributing to Healthcare Across Hokkaido Partial Free Access to MECCUL Database Establishment of A+north Medical Inc. March 2025 October 2025 (planned) Began offering some functions of the paid version
Slide 20: ORTHO EDGE JAPAN Co., Ltd. Surging Ahead!
Topics: Advancing to the Next Stage ORTHO EDGE JAPAN Co., Ltd. Surging Ahead! Established in July 2023 as a subsidiary of KURIBARA MEDICAL Instruments, the company began operations as a specialized trading firm focused on orthopedics. Since then, it has actively expanded its nationwide sales activit
Slide 21: Structure for Promoting Sustainability
Structure for Promoting Sustainability Board of Directors Reports & Supervises & Committee chair: recommends approves President and Representative Director Established July 2024 Sustainability Committee Executive committee chair: Director responsible for Liaises Sustainability sustainability Special
Slide 22: Sustainability: Identification of Material Issues
Sustainability: Identification of Material Issues • Set metrics & targets • Determine overall • Manage progress • Identify material issues • Integrate into business • Consider ESG issues • Spread Groupwide • Prioritize material issues policies awareness management • Plan & implement Material Issues
Slide 23: Sustainability: Climate Change Response
Sustainability: Climate Change Response To assess and manage the impact of climate-related issues on business management, the Group began calculating greenhouse gas (GHG) emissions (Scope 1–3) in FY2022 (July 2022–June 2023) based on the GHG Protocol, and continued doing so in FY2023 (July 2023–June
Slide 24: Sustainability: Promoting the Active Participation of All Human Resources
Sustainability: Promoting the Active Participation of All Human Resources Results for FYE 6/2024 Results for FYE 6/2025 Medius Medius Kuribara Medical Kyowa Medical Kuribara Medical Kyowa Medical Holdings co., Holdings co., Instruments Co., Ltd. Corporation Instruments Co., Ltd. Corporation Ltd. Ltd
Slide 25: Sustainability: Social Contribution Activities
Sustainability: Social Contribution Activities Donation to the UN World Food Programme Donation gift-matching for Médecins Sans (WFP) Red Cup Campaign Frontières (Doctors without Borders) The Red Cup Campaign subsidizes provision of school We conducted a donation gift-matching campaign, inviting mea
Slide 26: Sustainability: Social Contribution Activities
Sustainability: Social Contribution Activities Contributing to society alongside local Contributing to local social welfare initiatives communities through sport Projects in collaboration with local communities S-Pulse Social Welfare Fund ▶ Paper Cup Recycling Medius Group X Shimizu S-Pulse Kuribara
Slide 27: Sustainability: Social Contribution Activities
Sustainability: Social Contribution Activities Boosting medicine’s potential through the potential of the young Hands-on medical experience event, MEDI-Message Kyowa Medical Corporation & ALVAUS X MEDI-Message Executive Committee (Shizuoka Medical Association, etc.) We hold medical experience events
Slide 28: Overview of the FYE 6/2025: Net Sales
Overview of the FYE 6/2025 Net Sales Net Sales 288.6 billion yen ( Yo Y + 11 . 1 % ye a r o n ye a r / v s . i n i t i a l p l a n + 3 . 1 % ) ▶Year-on-year Increase due to increased surgical operations, acquisitions of new customers, full-year contribution from MAKOTO MEDICAL SYSTEMS INC., and sale
Slide 29: Overview of the FYE 6/2025: Profits
Overview of the FYE 6/2025 Profits Gross Profit 34.4 billion yen Operating Profit 1.87 billion yen (YoY +10.8% / vs. initial plan - ) (YoY +41.3% / vs. initial plan +34.0%) ▶Year-on-year Despite soaring cost of sales and lower reimbursement prices in June 2024, gross profit margin was maintained thr
Slide 30: Selling, general and administrative expenses
Overview of the FYE 6/2025 Selling, general and administrative expenses Selling, general and administrative expenses 32.56 billion yen (YoY +9.4%) (Of which) Personnel expenses 20.64 billion yen (YoY +9.4%) SGA Personnel expenses SGA expenses Personnel hiring due to business expansion（＋） expenses
Slide 31: Analysis of Factors Contributing to Operating Profit
Analysis of Factors Contributing to Operating Profit (Millions of yen) FYE 6/2024 FYE 6/2025 ＋548 million yen 1,327 million yen 1,875million yen Copyright©2025 Medius Holdings Co., Ltd. All Rights Reserved 31
Slide 32: Net Sales (Medical Equipment and Others)
Net Sales (Medical Equipment and Others) (Millions of yen) 340,000 332,650 41,207 300,918 12.4% 90.0% 300,000 278,299 37,914 259,574 38,025 12.6% 260,000 246,787 70.0% 33,592 13.7% 36,852 12.9% 220,000 14.9% 50.0% 180,000 291,442 263,004 87.6% 140,000 240,274 87.4% 30.0% 225,982 209,935 86.3% 87.1%,
Slide 33: Replacement Supplies FYE 6/2025 Net Sales by Category
Replacement Supplies FYE 6/2025 Net Sales by Category (Millions of yen) Catheterization/treatment Catheterization/treatment Orthopedic implants Others 47,827 Endoscope-related 102,215 Surgical instruments Cardiac surgery Orthopedic implants Personal Protective Equipment (PPE) 39,060 Ophthalmology Ot
Slide 34: Replacement Supplies Net Sales in Main Product Categories
Replacement Supplies Net Sales in Main Product Categories (FYE June 2021–FYE June 2025) (Millions of yen) 60,000 FYE 6/2021 FYE 6/2022 FYE 6/2023 FYE 6/2024 FYE 6/2025 50,000 40,000 30,000 20,000 10,000 0 Catheterization/treatment Orthopedic implants Endoscope-related Surgical instruments Cardiac su
Slide 35: Medical Equipment FYE 6/2025 Net Sales by Category
Medical Equipment FYE 6/2025 Net Sales by Category Radiological equipment (Millions of yen) Therapeutic Endoscopic examination & surgery electrosurgical instruments Ultrasound equipment 302 Blood purifiers Others Sample testing 336 7,443 Radiological equipment Monitors Surgical microscopes 7,043 371
Slide 36: Medical Equipment Net Sales in Main Product Categories
Medical Equipment Net Sales in Main Product Categories (FYE 6/2021–FYE 6/2025) (Millions of yen) 8,000 FYE 6/2021 FYE 6/2022 FYE 6/2023 FYE 6/2024 FYE 6/2025 7,000 6,000 5,000 4,000 3,000 2,000 1,000 0 Radiological Endoscopic Ultrasound Sample testing Monitors Ophthalmic equipment examination & equi
Slide 37: FYE 6/2026 Full-Year Financial Results Outlook
FYE 6/2026 Full-Year Financial Results Outlook (Millions of yen) FYE 6/2025 FYE 6/2026 Full-year Full-year YoY (Plan) Net sales 288,689 305,000 105.6% Operating profit 1,875 1,750 93.3% Ordinary profit 2,422 2,300 94.9% Profit attributable to owners of parent 1,375 1,300 94.5% Ratio of operating pro
Slide 38: Full-Year Financial Results Outlook for FYE 6/2026: Further Information
Full-Year Financial Results Outlook for FYE 6/2026: Further Information Net sales & gross profit Sales expansion driven by enhanced solution offerings and new SPD contracts Increase in testing and surgical operations, with new operations mainly in cardiology and orthopedics Cost of sales exp
Slide 39: Dividend Payout Ratio and Policy
Dividend Payout Ratio and Policy Dividend payout ratio The Company’s basic policy is to distribute the results commensurate with its growth while securing the internal reserves necessary to maintain stable growth over the medium to long term. To this end, the Company pays dividends with a target con
Slide 40: Management Conscious of Cost of Capital and Stock Price: Analysis of Current Situation
Management Conscious of Cost of Capital and Stock Price: Analysis of Current Situation The Company’s shareholders’ equity cost is estimated at 6% on a capital asset pricing model (CAPM) basis. ROE is now on a downward trajectory, having peaked during the FYE 6/2021, but it still exceeds the cost
Slide 41: Management Conscious of Cost of Capital and Stock Price: Measures
Management Conscious of Cost of Capital and Stock Price: Analysis of Current Situation Enhance business profitability Grow gross profit Expand sales of private brand Improve profitability products Expand business into new domains Restructure and strengthen Curb SGA expenses Enhance product
Slide 42: Management Philosophy
Management Philosophy Our philosophy remains unchanged since the Company’s founding Contributing to Community Hearthcare Copyright©2025 Medius Holdings Co., Ltd. All Rights Reserved 42
Slide 43: Medius Holdings Co., Ltd. Securities Code: 3154
Medius Holdings Co., Ltd. Securities Code: 3154 Our Business: Medical device sales and maintenance business Nursing care and welfare product sales and rental business Established July 2009 Capital 1.38 billion yen (Changed to present company name (As of June 30, 2025) in 2010) No. of employees 2,614
Slide 44: The Medius Group's Businesses
The Medius Group’s Businesses Medical Device Sales Business Welfare Device Business The Medius Group sells medical devices purchased from medical device manufacturers and others in Japan to medical institutions and The Medius Group sells and rents nursing care and undertakes repair and maintenance o
Slide 45: The Accounting Standard for Revenue Recognition
The Accounting Standard for Revenue Recognition The Company applied the Accounting Standard for Revenue Recognition in the FYE 6/2022. Impacts of applying standard For transactions in which the Medius Group acts as an agent, net sales are reduced because revenue is recognized based on the net am
Slide 46: Major Suppliers
Major Suppliers (in Japanese alphabetical order) Asahi Kasei Medical Co., Ltd. Tokyo Saraya Co., Ltd. Nihon Kohden Corporation Atom Medical Corporation Santen Pharmaceutical Co., Ltd. Stryker Japan K.K. Abbott Medical Japan LLC GE Healthcare Japan Corporation MC Medical, Inc. ALCARE Co., Ltd. Siemen
Slide 47: Medius Group Earnings Structure Seasonal
Medius Group Earnings Structure Seasonal Quarterly operating profit Seasonal factors 2,500 2,000 3Q: January to March • This is the end of the fiscal year for medical 1,500 institutions, so purchasing of medical equipment is concentrated at this time, driving up net sales. 1,000 4Q: April to June 50
Slide 48: Disclaimer Regarding Use of This Document
Disclaimer Regarding Use of This Document This document was prepared to facilitate understanding of Medius Holdings Co., Ltd. (the Company) and the Medius Group. It is not intended to solicit investment in the Company. Care was taken to ensure accuracy when preparing this document, but the Company d